hcplive podcasts

News Network

EP. 1: Recent Achievements in Psoriatic Arthritis Management

EP. 2: Fitting Biologics into the Psoriatic Arthritis Spectrum

EP. 3: Achieving Individualized Psoriatic Arthritis Care

EP. 4: Most Promising Psoriatic Arthritis

EP. 5: Highlighted Psoriatic Arthritis Sessions at ACR 2020

EP. 6: How Different Psoriatic Arthritis Manifestations Affect Care

EP. 7: The Modern Psoriatic Care Team

EP. 8: The Psoriatic Patient's Role in Improving Care

EP. 9: What Should Highlight ACR 2021

EP. 10: Current Issues in nr-axSpA Diagnostics

EP. 11: Takeaways from Four-Year RAPID-axSpA Data

EP. 12: Takeaways from the 52-Week C-axSpAnd Trial

EP. 1: Rheumatic Disease Challenges and Goals of Therapy

EP. 2: Psoriatic Arthritis Treatment Factors: Comorbidities

EP. 3: Data on COVID-19 in Patients With Rheumatic Disease

EP. 4: IL-6 Receptor Blockade in ICU Patients With COVID-19

EP. 5: Treatment Modification: ACR COVID-19 Guidelines

EP. 6: Accurately Diagnosing Psoriatic Arthritis

EP. 7: Guselkumab for Psoriatic Arthritis

EP. 8: Deucravacitinib for Active Psoriatic Arthritis

EP. 9: Treating Enthesitis in Psoriatic Arthritis Patients: Filgotinib

EP. 10: SELECT-PsA 1 and SELECT-PsA 2 in Psoriatic Arthritis

EP. 1: Overview of Schizophrenia

EP. 2: Challenges for the Treatment of Schizophrenia

EP. 3: Schizophrenia: Relapse Prevention and Adverse Effects

EP. 4: Schizophrenia: Treatment Adherence

EP. 5: Psychosocial Treatments for the Management of Schizophrenia

EP. 6: Use of Oral Therapy for the Management of Schizophrenia

EP. 7: Guidelines for the Treatment of Schizophrenia

EP. 8: Switching From Oral Therapy to Long-Acting Injectables

EP. 9: Initiating LAI Therapy for the Treatment of Schizophrenia

EP. 10: Management of Schizophrenia and Available LAIs

EP. 11: Overcoming Barriers With LAIs in Schizophrenia Management

EP. 12: Early Initiation of LAIs in Treating Schizophrenia

EP. 13: Recommendations for Using LAIs During COVID-19

x